日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data

利用真实世界数据和NATALEE数据,基于机器学习预测HR+/HER2-早期乳腺癌远处复发风险和瑞博西尼治疗效果

Howard, Frederick M; Fasching, Peter A; Santa-Maria, Cesar A; Lim, Elgene; Sparano, Joseph A; Lustberg, Maryam B; Bachelot, Thomas; Blyuss, Oleg; Brezden-Masley, Christine; Park, Yeon Hee; Akdere, Murat; Ye, Fen; Pantoja, Kristyn; Kurz, Christoph; Dominguez Castro, Patricia; Razavi, Pedram

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer

II-III期HR+/HER2-早期乳腺癌患者接受辅助内分泌治疗的真实世界复发风险和治疗结果

O'Shaughnessy, Joyce; Tolaney, Sara M; Yardley, Denise A; Hart, Lowell; Razavi, Pedram; Fasching, Peter A; Janni, Wolfgang; Schwartzberg, Lee; Kim, Julia; Akdere, Murat; McDermott, Courtney; Khakwani, Aamir; Pathak, Purnima; Graff, Stephanie L

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

对芳香化酶抑制剂与他莫昔芬治疗HR+/HER2-早期乳腺癌患者的系统性文献综述和试验水平荟萃分析

Janni, Wolfgang; Untch, Michael; Harbeck, Nadia; Gligorov, Joseph; Jacot, William; Chia, Stephen; Boileau, Jean-François; Gupta, Subhajit; Mishra, Namita; Akdere, Murat; Danyliv, Andriy; Curigliano, Giuseppe

Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer

在真实世界人群中,对HR+/HER2-早期乳腺癌患者的侵袭性疾病无进展生存期和总生存期进行相关性分析

Graff, Stephanie L; Tolaney, Sara M; Hart, Lowell L; Razavi, Pedram; Janni, Wolfgang; Schwartzberg, Lee S; Danyliv, Andriy; Akdere, Murat; Ferrusi, Ilia; Adhikary, Rishi Rajat; O'Shaughnessy, Joyce A

Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer

在激素受体阳性/HER2阴性早期乳腺癌中,瑞博西尼+非甾体类芳香化酶抑制剂与阿贝西利+内分泌治疗的匹配调整间接比较

Chia, Stephen; Li, Jie; Ma, Fei; Stellato, Daniel; Danyliv, Andriy; Ferrusi, Ilia; Hu, Huilin; Akdere, Murat; Makris, Andreas

SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.

SGLT2 抑制剂可改善 PI3Kα 抑制剂引起的血糖升高:来自临床前动物模型和 BYLieve 和 SOLAR-1 试验患者的研究结果

Borrego Manuel Ruiz, Lu Yen-Shen, Reyes-Cosmelli Felipe, Park Yeon Hee, Yamashita Toshinari, Chiu Joanne, Airoldi Mario, Turner Nicholas, Fein Luis, Ghaznawi Farhat, Singh Jyotika, Pantoja Kristyn, Schnell Christian, Akdere Murat, Chia Stephen